Clinical trial
A Phase 1 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetic Characterization of KQ-2003 for Patients With Relapsed/Refractory POEMS Syndrome
NCT06518876 is registered in ClinicalTrials.gov with Novatim Immune Therapeutics (Zhejiang) Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetic Characterization of KQ-2003 for Patients With Relapsed/Refractory POEMS Syndrome
- Lead sponsor
- Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- August 31, 2024
- Completion date
- December 31, 2027
- Enrollment
- 21 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.